Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-000867
Filing Date
2025-02-12
Accepted
2025-02-12 16:28:00
Documents
76
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q rzlt-20241231x10q.htm   iXBRL 10-Q 1418088
2 EX-31.1 rzlt-20241231xex31d1.htm EX-31.1 15229
3 EX-32.1 rzlt-20241231xex32d1.htm EX-32.1 7271
  Complete submission text file 0001558370-25-000867.txt   7355850

Data Files

Seq Description Document Type Size
4 EX-101.SCH rzlt-20241231.xsd EX-101.SCH 53823
5 EX-101.CAL rzlt-20241231_cal.xml EX-101.CAL 38948
6 EX-101.DEF rzlt-20241231_def.xml EX-101.DEF 227809
7 EX-101.LAB rzlt-20241231_lab.xml EX-101.LAB 434560
8 EX-101.PRE rzlt-20241231_pre.xml EX-101.PRE 379490
79 EXTRACTED XBRL INSTANCE DOCUMENT rzlt-20241231x10q_htm.xml XML 1359816
Mailing Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065
Business Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065 650-206-4507
Rezolute, Inc. (Filer) CIK: 0001509261 (see all company filings)

EIN.: 273440894 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39683 | Film No.: 25615229
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)